Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).
Clinical Benefit
| Substantial |
The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication. |
Clinical Added Value
| important |
SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS. |
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
BVzm70SGueymBD9g
Listen
